Hemenway Trust Co LLC Reduces Holdings in Novo Nordisk A/S $NVO

Key Points

• Hemenway Trust Co LLC cut its Novo Nordisk stake by 76.9%, selling 60,077 shares and leaving 18,090 shares valued at about $920,000 at quarter-end.
• Novo Nordisk announced a new share repurchase programme (part of a DKK 15 billion plan) and is seeing strong early demand for its Wegovy pill, which could support near‑term revenue momentum and market share gains.
• Offsetting positives, analysts warn of pricing pressure and a potential price war with Eli Lilly that could compress margins; the consensus rating is currently a Hold with a $65.56 average price target.

Hemenway Trust Co LLC lessened its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 76.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,090 shares of the company's stock after selling 60,077 shares during the period. Hemenway Trust Co LLC's holdings in Novo Nordisk A/S were worth $920,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in NVO. WJ Financial Advisors LLC lifted its holdings in Novo Nordisk A/S by 134.2% during the 4th quarter. WJ Financial Advisors LLC now owns 12,058 shares of the company's stock worth $614,000 after purchasing an additional 6,909 shares in the last quarter. Chung Wu Investment Group LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter worth about $305,000. Pittenger & Anderson Inc. lifted its holdings in Novo Nordisk A/S by 915.0% during the 4th quarter. Pittenger & Anderson Inc. now owns 1,015 shares of the company's stock worth $52,000 after purchasing an additional 915 shares in the last quarter. Dudley Capital Management LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter worth about $361,000. Finally, Aurora Private Wealth Inc. purchased a new stake in Novo Nordisk A/S during the 4th quarter worth about $350,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Company announces a new share repurchase programme as part of an existing DKK 15 billion plan, supporting buybacks and shareholder returns. Novo Nordisk A/S - share repurchase programme
• Positive Sentiment: Coverage highlights Wegovy’s early pill rollout and strong demand, reinforcing Novo Nordisk’s leadership in GLP‑1 weight-loss treatments and suggesting continued revenue momentum. Novo Nordisk's Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance
• Positive Sentiment: Safety signals tied to Eli Lilly’s Foundayo (FDA reports of serious liver events) may indirectly benefit Novo Nordisk by slowing competitor adoption and keeping market share growth for Wegovy and related products more favorable. FDA Reports Liver Failure in Patient Taking Eli Lilly’s Foundayo
• Positive Sentiment: Bullish investor pieces argue Q1 could mark an inflection (top- and bottom-line beats expected), and some investors are “doubling down” based on the growth runway for GLP‑1s and strategic pricing to expand market share. Novo Nordisk: My Q1 Preview And Why I'm Doubling Down
• Neutral Sentiment: Sector analysis notes GLP‑1s have reshaped pharma R&D value and improved returns, which supports longer‑term demand for Novo Nordisk products but also attracts competition and regulatory scrutiny. 'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds
• Negative Sentiment: Reuters and other coverage warn a price war with Eli Lilly could compress margins — investors want evidence that rising prescriptions and volumes will offset lower prices. Novo Nordisk's weight-loss pill boom faces price war test
• Negative Sentiment: Pre‑earnings previews flag ongoing pricing pressure, potential weak guidance and tough competition from Eli Lilly as risks that could weigh on near‑term earnings and margins. Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Nordea Equity Research cut Novo Nordisk A/S to a "hold" rating in a report on Tuesday, February 24th. Weiss Ratings cut Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a report on Wednesday, April 22nd. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Kepler Capital Markets cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Tuesday, February 24th. Finally, Sanford C. Bernstein assumed coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They set an "outperform" rating and a $175.00 price objective on the stock. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Hold" and a consensus price target of $65.56.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $44.87 on Wednesday. The business's 50-day moving average price is $38.45 and its two-hundred day moving average price is $47.11. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The stock has a market cap of $200.34 billion, a P/E ratio of 12.93, a PEG ratio of 10.54 and a beta of 0.77. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion for the quarter, compared to analysts' expectations of $11.97 billion. As a group, equities analysts predict that Novo Nordisk A/S will post 3.34 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.